Vivani Medical reports no treatment-related adverse events for semaglutide implant in Phase 1 trial
VANI•Vivani Medical reported no treatment-related adverse events among recipients of its NPM-139 semaglutide implant in the Phase 1 SLIM-1 trial. Weight loss was comparable to the Wegovy injection group, and a Phase 2 weight-maintenance trial is expected to begin in 2027.
1. SLIM-1 results
Vivani Medical reported positive top-line results from SLIM-1, a Phase 1 trial comparing its NPM-139 semaglutide implant with Wegovy injections. No implant recipients experienced treatment-related adverse events; gastrointestinal events occurred in the Wegovy group, and weight loss was comparable between the groups.
2. Next trial plans
The implant showed no rapid increases in drug exposure. Vivani expects to begin a Phase 2 dose-ranging weight-maintenance trial in 2027. The implant is designed for once- or twice-yearly administration, and development could expand to patients new to GLP-1 treatment based on the tolerability findings.
